The Northumbria University team have developed a new technology to move drugs into the body from a layer in a patch stuck to the skin. This is an alternative to using needles. Current drug delivery patches don’t work for a large proportion of drugs because of their chemistry characteristics mean they don’t absorb through skin well. This technology can move ‘difficult’ molecules through the skin.
The initial brief of the executive will be to:
(1) Produce a viable 5 year business plan;
(2) Obtain university approval for the venture;
a. Act for the company in the spin-out legal process and address all company formation matters;
b. Provide to the appropriate university all matters necessary for Research England reporting requirements;
(3) Secure a Medical Device Manufacturer partnership
(4) Engage with investors in securing funding
Newcastle, Sunderland, Northumbria, Durham, Teesside universities together with the University of Bath on
behalf of the SETsquared Partnership (the Enterprise collaboration of the Universities of Bath, Bristol, Exeter,
Southampton and Surrey) and any other HE Institution that wishes to join this DPS, as detailed in the Office for Students Register, https://www.officeforstudents.org.uk/advice-and-guidance/the-register/the-ofs-register/ will engage suitably qualified and experienced executives through the DPS as and when required over the DPS period.
The specific requirements will be detailed in each individual further competition. The typical brief of an executive will be to:
(a) Produce a viable business plan;
(b) Obtain university approval for the venture;
(c) Act for the company in the spin-out legal process and address all company formation matters;
(d) Provide to the appropriate university all matters necessary for Research England and ESIF reporting
requirements;
(e) Secure (venture capital and/or other) funding in accordance with the business plan.
This will be a cyclical process throughout the entire Research England, and potential ESIF project along with any additional funding streams.